Swiss National Bank
YMAB

Swiss National Bank’s Y-mAbs Therapeutics YMAB Stock Holding History

Swiss National Bank’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-60,300
Closed -$472K – 2452
2024
Q4 		$472K Hold
60,300
– – ﹤0.01% 2409
2024
Q3 		$793K Hold
60,300
– – ﹤0.01% 2313
2024
Q2 		$728K Buy
+60,300
New +$814K ﹤0.01% 2302
2023
Q1 		– Sell
-77,100
Closed -$376K – 2673
2022
Q4 		$376K Hold
77,100
– – ﹤0.01% 2622
2022
Q3 		$1.11M Hold
77,100
– – ﹤0.01% 2277
2022
Q2 		$1.17M Buy
77,100
+15,100
+24% +$176K ﹤0.01% 2274
2022
Q1 		$737K Buy
62,000
+4,700
+8% +$48.3K ﹤0.01% 2509
2021
Q4 		$929K Hold
57,300
– – ﹤0.01% 2507
2021
Q3 		$1.64M Hold
57,300
– – ﹤0.01% 2177
2021
Q2 		$1.94M Buy
57,300
+11,000
+24% +$353K ﹤0.01% 2122
2021
Q1 		$1.4M Buy
46,300
+1,200
+3% +$49.2K ﹤0.01% 2207
2020
Q4 		$2.23M Hold
45,100
– – ﹤0.01% 1835
2020
Q3 		$1.73M Buy
45,100
+700
+2% +$27.9K ﹤0.01% 1793
2020
Q2 		$1.92M Buy
44,400
+5,900
+15% +$223K ﹤0.01% 1738
2020
Q1 		$1M Buy
38,500
+1,100
+3% +$31.9K ﹤0.01% 1823
2019
Q4 		$1.17M Buy
37,400
+24,700
+194% +$731K ﹤0.01% 2054
2019
Q3 		$331K Hold
12,700
– – ﹤0.01% 2444
2019
Q2 		$290K Buy
+12,700
New +$292K ﹤0.01% 2519

Other funds holding YMAB

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

Swiss National Bank's YMAB Position: Q1 2025 in Review

Swiss National Bank sold out of Y-mAbs Therapeutics (YMAB) in Q1 2025, closing a stake of 60,300 shares — an estimated $472K sold.

Swiss National Bank first reported a position in YMAB in Q2 2019 and held it in 18 quarters. The position peaked at $2.23M in Q4 2020. 102 funds tracked by Wall St. Rank hold YMAB as of Q1 2025.

  • Swiss National Bank reported no remaining Y-mAbs Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Swiss National Bank sold 60,300 Y-mAbs Therapeutics shares in Q1 2025, an estimated $472K.
  • Swiss National Bank first reported a position in Y-mAbs Therapeutics in Q2 2019 and held it in 18 quarters.
  • Swiss National Bank's Y-mAbs Therapeutics position peaked at $2.23M in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2025.

Based on Swiss National Bank's 13F filing for Q1 2025, filed 12 May 2025.